Avidity Biosciences FDA Removed Partial Clinical Hold On Delpacibart Etedesiran (Del-Desiran/AOC 1001), An Investigational Treatment Designed To Address Root Cause Of Myotonic Dystrophy Type 1
Portfolio Pulse from Benzinga Newsdesk
Avidity Biosciences announced that the FDA has removed the partial clinical hold on Delpacibart Etedesiran (Del-Desiran/AOC 1001), an investigational treatment for Myotonic Dystrophy Type 1. This development allows the company to proceed with its clinical trials.
October 03, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA has lifted the partial clinical hold on Avidity Biosciences' Delpacibart Etedesiran, allowing the company to continue its clinical trials for Myotonic Dystrophy Type 1 treatment.
The lifting of the FDA's partial clinical hold is a significant regulatory milestone for Avidity Biosciences, allowing them to proceed with clinical trials. This is likely to be viewed positively by investors as it indicates progress in the development of a treatment for Myotonic Dystrophy Type 1.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100